StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.87+1.77 (+6.30%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

UroGen Pharma's ebitda for the twelve months ending Jun 30, 2026 was -$66.30M. For fiscal 2025 it was -$124.56M. The highest annual figure on record is $998.00K in fiscal 2016.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$124.56M–
FY2024Dec 31, 2024-$96.45M–
FY2023Dec 31, 2023-$64.73M–
FY2022Dec 31, 2022-$78.12M–
FY2021Dec 31, 2021-$91.46M–
FY2020Dec 31, 2020-$126.32M–
FY2019Dec 31, 2019-$109.18M–
FY2018Dec 31, 2018-$76.78M–
FY2017Dec 31, 2017-$19.75M-2079.0%
FY2016Dec 31, 2016$998.00K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$211.00K–
Q1 FY2026Mar 31, 2026-$20.19M–
Q4 FY2025Dec 31, 2025-$19.04M–
Q3 FY2025Sep 30, 2025-$27.29M–
Q2 FY2025Jun 30, 2025-$41.35M–
Q1 FY2025Mar 31, 2025-$36.84M–
Q4 FY2024Dec 31, 2024-$27.59M–
Q3 FY2024Sep 30, 2024-$17.45M–
Q2 FY2024Jun 30, 2024-$25.74M–
Q1 FY2024Mar 31, 2024-$25.62M–
Q4 FY2023Dec 31, 2023-$14.42M–
Q3 FY2023Sep 30, 2023-$13.30M–
Q2 FY2023Jun 30, 2023-$15.18M–
Q1 FY2023Mar 31, 2023-$21.83M–
Q4 FY2022Dec 31, 2022-$20.05M–
Q3 FY2022Sep 30, 2022-$17.89M–
Q2 FY2022Jun 30, 2022-$18.52M–
Q1 FY2022Mar 31, 2022-$21.74M–
Q4 FY2021Dec 31, 2021-$19.70M–
Q3 FY2021Sep 30, 2021-$23.24M–
Q2 FY2021Jun 30, 2021-$22.62M–
Q1 FY2021Mar 31, 2021-$25.92M–
Q4 FY2020Dec 31, 2020-$27.13M–
Q3 FY2020Sep 30, 2020-$29.02M–
Q2 FY2020Jun 30, 2020-$31.70M–
Q1 FY2020Mar 31, 2020-$38.46M–
Q4 FY2019Dec 31, 2019-$39.74M–
Q3 FY2019Sep 30, 2019-$23.35M–
Q2 FY2019Jun 30, 2019-$23.65M–
Q1 FY2019Mar 31, 2019-$22.33M–
Q4 FY2018Dec 31, 2018-$23.82M–
Q3 FY2018Sep 30, 2018-$20.99M–
Q2 FY2018Jun 30, 2018-$18.39M–
Q1 FY2018Mar 31, 2018-$13.44M–

More UroGen Pharma figures

See a number that looks wrong?